remifantanil

PreclinicalSmall molecule

AAjou University School of Medicine

remifantanil is one of 5 small molecule programs targeting Loss of consciousness. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Loss of ConsciousnessActive, not recruiting

Loss of ConsciousnessPreclinical

Active, not recruiting

Competition

Competitive Landscape

8 competitors in Loss of Consciousness

#DrugCompanyPhaseTrials

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

3 2

Versed

CConrado Roberto Hoffmann Filho

Preclinical

2 3

Anerem

AAcacia Pharma Ltd

Preclinical

1 4

Sufenta

LLeaf Vertical Inc.

Preclinical

—5

remifantanil

AAjou University School of Medicine

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Loss of consciousness1 trial

The Effect of Remifentanil on ED95 of Remimazolam for Loss of Consciousness in Adult Patients

Unknown status·—·N/A·NCT05434494·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for remifantanil. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — remifantanil compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for remifantanil. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ajou University School of Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AAjou University School of Medicine

remifantanil

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Loss of consciousness1 trial

References

Drug Info

Quick Facts

Related News